The investment of around €7 million significantly enhances the site’s flexibility and capacity in synthesizing modern, complex and even corrosive molecules
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Although PCM has advanced substantially in recent years, most of the valuable technical information resides with private companies and academic publications across multiple platforms
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Supply increase to help meet growing global demand
The company inaugurated the new production line at the Bengaluru facility to manufacture Computed Tomography Scanners
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
The expansion makes Exothera one of the largest viral vector facilities in Europe
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Subscribe To Our Newsletter & Stay Updated
